Pardes Biosciences (PRDS) to Be Acquired by MediPacific for $2.02-$2.19 Per Share
by Nicholas Alan Clayton on 2023-07-17 at 8:46am

Pardes Biosciences (NASDAQ:PRDS), which combined with FS Development Corp. II in December 2021, announced that it has agreed to be acquired by MediPacific for $2.02 to $2.19 per share for a premium of 8%-17% over its last closing price.

A tender offer for the company will launch on July 28 to acquire all outstanding Pardes shares within this price range. A MediPacific subsidiary will also receive a contingent value right (CVR) promising it 80% of net proceeds from any license of Pardes assets over the first five years following close.

Pardes’ main drug candidate Pomotrelvir is designed to inhibit the reproduction of coronavirus cells. It demonstrated potential effectiveness in Phase I trials against recent COVID-19 variant Omicron as well as the MERS and SARS variants discovered earlier.

But, its initial readouts from Phase II trials dropped in April and it did not meet its primary endpoint in producing better outcomes than a placebo.

Patients were otherwise healthy, vaccinated adults that had been infected with COVID-19 and although patients in both groups had dropping viral loads and improved health, the data indicated it was likely the vaccine rather than Pomotrelvir doing most of the work.

Pardes stock was in a slump even before these results, however. Having hit a post-close high of $16.88 in January 2022, it has traded below $5 since June 2022, despite being well-funded with just 1.2% redemptions from FS II’s $200 million trust.

But, as the world moved on from COVID, the market appears to have moved on from potential breakthroughs in treating it as well. Having hit an initial dead end with Pomotrelvir’s Phase II, the company announced it would suspend its development and seek out strategic alternatives.

From this standpoint, Pardes may be considered fortunate that it will still be effectively valued at about $130 million in this take-private.


Recent Posts
by Nicholas Alan Clayton on 2023-12-11 at 10:45am

SEC Chair Gary Gensler made waves with public remarks last week noting that the agency would be looking at potentially making enforcement actions against companies found to be “AI-washing” their descriptions of business operations, claiming to have an artificial intelligence angle where one does not exist. He did not connect this issue with SPACs directly,...

by Nicholas Alan Clayton on 2023-12-11 at 7:57am

At the SPAC of Dawn This week is set to see SPACs rush to tie up business combinations nicely in a bow before the final two weeks of the year. Eight SPACs currently have completion votes on the docket this week, while there are currently just four more booked for the rest of 2023. Eight...

by Marlena Haddad on 2023-12-11 at 7:52am

SportsMap Tech Acquisition Corp. (NASDAQ:SMAP) announced this morning that its shareholders approved its business combination with intelligent thermal imaging provider Infrared Cameras Holdings (ICI) during a special meeting on December 8. A total of 3,829,673 shares of the common stock, representing approximately 73.86% of the issued and outstanding shares, were present at the meeting, constituting...

by Kristi Marvin on 2023-12-09 at 11:45am

Terms Tracker for the Week Ending December 8, 2023 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. Well that escalated quickly. While last week was quiet, this week was far busier. SPACs saw one IPO start trading after pricing on Friday of...

by Marlena Haddad on 2023-12-08 at 1:59pm

Mobiv Acquisition Corp. (NASDAQ:MOBV) announced this afternoon that it has closed its combination with EV motorcycle-maker SRIVARU. Shareholders originally approved the deal at a special meeting held back on September 28, but at that time, the parties expected the transaction to take just a week to close. Redemptions whittled Mobiv’s IPO share pool of 10,005,000 down...


Copyright © 2023 SPACInsider, Inc. All Rights Reserved